Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL19001 intravesical therapy with or without BCG in high-risk NMIBC (Phase I/II)
ChiCTR2600120806Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of JL19001 in bladder cancer (5 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Tolerability and safety and Phase II primary efficacy (12-month CRR/DFR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JL19001
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2600120806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120806.